Inhaltsseite: Home

Yield Enhancement

Nestlé and Roche with convincing quarterly figures

Friday, 22 October 2021 Reading time : 3 minutes

The two index heavyweights Nestlé and Roche presented their quarterly figures last Wednesday; both traditional companies were convincing with their results.

Nestlé reported organic sales growth of 7.6%, beating not only analysts' expectations but also the results of rival Danone. Almost 70% of analysts recommend buying the stock, 30% expect market performance. ZKB Equity Research rates the stock as "overweight".

Roche's two divisions (Pharmaceuticals and Diagnostics) are also presenting strong quarters, which has enabled the group to revise its sales forecasts upwards. Roche also receives an "overweight" rating from ZKB Equity Research.

Accordingly, the market consensus forecasts an upward trend for these two stocks - In the case of barrier products, the probability of a barrier hit is thus assessed as lower while the coupon remains unchanged.

Callable BRC on Nestlé and Roche

  • 6.5%* Coupon p.a.
  • 70%* Barrier
  • 18 months Maturity
  • Subscription deadline October 27, 2021
  • Termsheet

Callable BRC on Nestlé and Roche
  • 5%* Coupon p.a.
  • 65%* Barrier
  • 18 months Term
  • Subscription deadline October 27, 2021
  • Termsheet
With an outperformance certificate, direct participation in the share price development is also possible; investors who assume rising prices receive a participation rate of 185% up to the cap. 

Capped Outperformance Certificate on Roche

  • 185% participation
  • 110% cap level
  • 12 months term
  • Subscription deadline October 27, 2021
  • Valor 113 973 917
*indicative
Advanced search
/home/search/guidepost.html /home/general/quick_search_live.html

Current products

Ajax loading